Limits...
Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation.

Capriotti K, Capriotti JA - Clin Cosmet Investig Dermatol (2015)

Bottom Line: Nail changes associated with chemotherapy in general, and particularly with taxane and epidermal growth factor receptor inhibitor-based regimens, are common presentations in our clinical population.The patient's chemotherapy regimen included doxorubicin, cyclophosphamide, and docetaxel.The topical povidone-iodine/dimethylsulfoxide system is very effective in alleviating the signs and symptoms of severe paronychia associated with chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: ALC Therapeutics, LLC, Springhouse, PA, USA ; Bryn Mawr Skin and Cancer Institute, Rosemont, PA, USA.

ABSTRACT

Background: Nail changes associated with chemotherapy in general, and particularly with taxane and epidermal growth factor receptor inhibitor-based regimens, are common presentations in our clinical population. Currently, there are no consensuses about therapies supported by clinical trials nor are there any US Food and Drug Administration-approved treatments for this indication.

Findings: A 42-year-old woman with stage 2A breast cancer presented to our clinic with chemotherapy-induced paronychia. Symptoms were severe enough that cessation of chemotherapy was being considered. The patient's chemotherapy regimen included doxorubicin, cyclophosphamide, and docetaxel.

Conclusion: The topical povidone-iodine/dimethylsulfoxide system is very effective in alleviating the signs and symptoms of severe paronychia associated with chemotherapy. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.

No MeSH data available.


Related in: MedlinePlus

Baseline treatment.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590550&req=5

f1-ccid-8-489: Baseline treatment.

Mentions: Physical examination revealed mild periungual swelling and erythema of eight fingernails. Serosanginous crusting/exudate and granulation tissue also involved the proximal nail folds (Figure 1). Toenails were not involved. A diagnosis of chemotherapy-associated paronychia was made.


Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation.

Capriotti K, Capriotti JA - Clin Cosmet Investig Dermatol (2015)

Baseline treatment.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590550&req=5

f1-ccid-8-489: Baseline treatment.
Mentions: Physical examination revealed mild periungual swelling and erythema of eight fingernails. Serosanginous crusting/exudate and granulation tissue also involved the proximal nail folds (Figure 1). Toenails were not involved. A diagnosis of chemotherapy-associated paronychia was made.

Bottom Line: Nail changes associated with chemotherapy in general, and particularly with taxane and epidermal growth factor receptor inhibitor-based regimens, are common presentations in our clinical population.The patient's chemotherapy regimen included doxorubicin, cyclophosphamide, and docetaxel.The topical povidone-iodine/dimethylsulfoxide system is very effective in alleviating the signs and symptoms of severe paronychia associated with chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: ALC Therapeutics, LLC, Springhouse, PA, USA ; Bryn Mawr Skin and Cancer Institute, Rosemont, PA, USA.

ABSTRACT

Background: Nail changes associated with chemotherapy in general, and particularly with taxane and epidermal growth factor receptor inhibitor-based regimens, are common presentations in our clinical population. Currently, there are no consensuses about therapies supported by clinical trials nor are there any US Food and Drug Administration-approved treatments for this indication.

Findings: A 42-year-old woman with stage 2A breast cancer presented to our clinic with chemotherapy-induced paronychia. Symptoms were severe enough that cessation of chemotherapy was being considered. The patient's chemotherapy regimen included doxorubicin, cyclophosphamide, and docetaxel.

Conclusion: The topical povidone-iodine/dimethylsulfoxide system is very effective in alleviating the signs and symptoms of severe paronychia associated with chemotherapy. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.

No MeSH data available.


Related in: MedlinePlus